

Christine Y Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6008758/publications.pdf>

Version: 2024-02-01

130
papers

2,787
citations

218677

26
h-index

223800

46
g-index

131
all docs

131
docs citations

131
times ranked

4199
citing authors

#	ARTICLE	IF	CITATIONS
1	Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS ONE, 2015, 10, e0140002.	2.5	183
2	Major Physical Health Conditions and Risk of Suicide. American Journal of Preventive Medicine, 2017, 53, 308-315.	3.0	182
3	Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ, The, 2014, 348, g3596-g3596.	6.0	172
4	Missing clinical and behavioral health data in a large electronic health record (EHR) system. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 1143-1149.	4.4	112
5	Racial-Ethnic Differences in Psychiatric Diagnoses and Treatment Across 11 Health Care Systems in the Mental Health Research Network. Psychiatric Services, 2016, 67, 749-757.	2.0	95
6	Racial/Ethnic Differences in Health Care Visits Made Before Suicide Attempt Across the United States. Medical Care, 2015, 53, 430-435.	2.4	89
7	Substance use disorders and risk of suicide in a general US population: a case control study. Addiction Science & Clinical Practice, 2020, 15, 14.	2.6	76
8	Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. Journal of Clinical Epidemiology, 2011, 64, 223-228.	5.0	74
9	Diabetes Outpatient Care and Acute Complications Before and After High-Deductible Insurance Enrollment. JAMA Internal Medicine, 2017, 177, 358.	5.1	73
10	Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. Journal of Clinical Oncology, 2018, 36, 1121-1127.	1.6	70
11	Variation in patterns of health care before suicide: A population case-control study. Preventive Medicine, 2019, 127, 105796.	3.4	70
12	Unintended Impacts of a Medicaid Prior Authorization Policy on Access to Medications for Bipolar Illness. Medical Care, 2010, 48, 4-9.	2.4	68
13	Diagnosed Mental Health Conditions and Risk of Suicide Mortality. Psychiatric Services, 2019, 70, 750-757.	2.0	51
14	Effect of High-Deductible Insurance on High-Acuity Outcomes in Diabetes: A Natural Experiment for Translation in Diabetes (NEXT-D) Study. Diabetes Care, 2018, 41, 940-948.	8.6	44
15	High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes. Annals of Internal Medicine, 2018, 169, 845.	3.9	41
16	Ending the Diagnostic Odyssey—Is Whole-Genome Sequencing the Answer?. JAMA Pediatrics, 2020, 174, 821.	6.2	39
17	Prior Authorization for Antidepressants in Medicaid. Archives of Internal Medicine, 2009, 169, 750.	3.8	36
18	Trend and geographic analysis of the prevalence of dengue in Taiwan, 2010–2015. International Journal of Infectious Diseases, 2017, 54, 43-49.	3.3	36

#	ARTICLE	IF	CITATIONS
19	How complete are E&codes in commercial plan claims databases?. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 218-220.	1.9	34
20	10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan&TM's National Health Insurance Research Database. <i>BMJ Open</i> , 2017, 7, e014150.	1.9	34
21	Association Between Prior Authorization for Medications and Health Service Use by Medicaid Patients With Bipolar Disorder. <i>Psychiatric Services</i> , 2011, 62, 186-193.	2.0	33
22	Determinants of patient-reported medication errors: a comparison among seven countries. <i>International Journal of Clinical Practice</i> , 2011, 65, 733-740.	1.7	31
23	Impact of Prior Authorization on the Use and Costs of Lipid-Lowering Medications Among Michigan and Indiana Dual Enrollees in Medicaid and Medicare: Results of a Longitudinal, Population-Based Study. <i>Clinical Therapeutics</i> , 2011, 33, 135-144.	2.5	31
24	Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group. <i>Value in Health</i> , 2016, 19, 577-587.	0.3	31
25	Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: Results of a longitudinal, population-based study. <i>Clinical Therapeutics</i> , 2010, 32, 729-741.	2.5	30
26	Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. <i>Journal of Personalized Medicine</i> , 2018, 8, 19.	2.5	30
27	Direct-to-Consumer Genetic Testing and Potential Loopholes in Protecting Consumer Privacy and Nondiscrimination. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1869.	7.4	28
28	New users of antidepressant medications: first episode duration and predictors of discontinuation. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 65-71.	1.9	26
29	Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. <i>Genetics in Medicine</i> , 2018, 20, 1544-1553.	2.4	25
30	The evolution of Taiwan&TM's National Health Insurance drug reimbursement scheme. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2015, 23, 15.	2.0	24
31	Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis. <i>BMJ Open</i> , 2016, 6, e008671.	1.9	24
32	Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan&TM's National Health Insurance Research Database. <i>PLoS ONE</i> , 2018, 13, e0204206.	2.5	24
33	Direct-to-Consumer Genetic Testing Data Privacy: Key Concerns and Recommendations Based on Consumer Perspectives. <i>Journal of Personalized Medicine</i> , 2019, 9, 25.	2.5	24
34	Barriers to access and use of high cost medicines: A review. <i>Health Policy and Technology</i> , 2015, 4, 191-214.	2.5	23
35	Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001&dashrightarrow;2016). <i>Breast</i> , 2018, 38, 7-13.	2.2	23
36	Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans. <i>JAMA Cardiology</i> , 2017, 2, 1164.	6.1	22

#	ARTICLE	IF	CITATIONS
37	General Medical, Mental Health, and Demographic Risk Factors Associated With Suicide by Firearm Compared With Other Means. <i>Psychiatric Services</i> , 2018, 69, 677-684.	2.0	22
38	Association between the 2012 Health and Social Care Act and specialist visits and hospitalisations in England: A controlled interrupted time series analysis. <i>PLoS Medicine</i> , 2017, 14, e1002427.	8.4	22
39	Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand. <i>PLoS ONE</i> , 2015, 10, e0119945.	2.5	21
40	Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?. <i>Breast</i> , 2013, 22, 482-487.	2.2	20
41	A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. <i>Genetics in Medicine</i> , 2018, 20, 390-396.	2.4	20
42	Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016). <i>Breast Cancer Research and Treatment</i> , 2018, 171, 151-159.	2.5	20
43	Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 449-459.	2.5	20
44	Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review. <i>Journal of Personalized Medicine</i> , 2019, 9, 32.	2.5	20
45	Impact of ICD-10-CM Transition on Mental Health Diagnoses Recording. <i>EGEMS (Washington, DC)</i> , 2019, 7, 14.	2.0	20
46	Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: An interrupted time series study. <i>Health Policy</i> , 2014, 116, 196-205.	3.0	19
47	Net Clinical Benefit of Oral Anticoagulants: A Multiple Criteria Decision Analysis. <i>PLoS ONE</i> , 2015, 10, e0124806.	2.5	19
48	Randomized prospective evaluation of genome sequencing versus standard-of-care as a first molecular diagnostic test. <i>Genetics in Medicine</i> , 2021, 23, 1689-1696.	2.4	17
49	The Mediating Effect of Sleep Disturbance on the Relationship Between Nonmalignant Chronic Pain and Suicide Death. <i>Pain Practice</i> , 2019, 19, 382-389.	1.9	16
50	Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. <i>Genetics in Medicine</i> , 2021, 23, 1366-1371.	2.4	16
51	Tailoring access to high cost, genetically targeted drugs. <i>Medical Journal of Australia</i> , 2005, 182, 607-608.	1.7	15
52	Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. <i>Clinical Therapeutics</i> , 2015, 37, 1280-1291.	2.5	15
53	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. <i>BMJ Open</i> , 2017, 7, e014439.	1.9	15
54	Association Between Switching to a High-Deductible Health Plan and Major Cardiovascular Outcomes. <i>JAMA Network Open</i> , 2020, 3, e208939.	5.9	15

#	ARTICLE	IF	CITATIONS
55	Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study. <i>BMJ Open</i> , 2016, 6, e011322.	1.9	14
56	Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. <i>BMJ Open</i> , 2020, 10, e033427.	1.9	14
57	Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 25-32.	1.4	13
58	State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. <i>Value in Health</i> , 2018, 21, 692-697.	0.3	13
59	Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014). <i>British Journal of Cancer</i> , 2018, 118, 441-447.	6.4	13
60	Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States. <i>Journal of Personalized Medicine</i> , 2019, 9, 9.	2.5	13
61	Influence of Sleep Stage on LH Pulse Initiation in the Normal Late Follicular Phase and in Polycystic Ovary Syndrome. <i>Neuroendocrinology</i> , 2018, 107, 60-72.	2.5	11
62	The case for implementing sustainable routine, population-level genomic reanalysis. <i>Genetics in Medicine</i> , 2020, 22, 815-816.	2.4	11
63	A Global Review on the Utility of Genetic Testing for Familial Hypercholesterolemia. <i>Journal of Personalized Medicine</i> , 2020, 10, 23.	2.5	11
64	Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases. <i>Clinical Rheumatology</i> , 2009, 28, 371-377.	2.2	10
65	Changes in use of antidiabetic medications following price regulations in China (1999-2009). <i>Journal of Pharmaceutical Health Services Research</i> , 2013, 4, 3-11.	0.6	10
66	How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?. <i>Clinical Therapeutics</i> , 2015, 37, 1420-1432.e1.	2.5	10
67	Dermatologic Conditions and Risk of Suicide: A Case-Control Study. <i>Psychosomatics</i> , 2018, 59, 58-61.	2.5	10
68	Use of assisted reproductive technologies before and after the Artificial Reproduction Act in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0206208.	2.5	10
69	Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 235-242.	2.5	10
70	Effect of high-deductible insurance on health care use in bipolar disorder. <i>American Journal of Managed Care</i> , 2020, 26, 248-255.	1.1	10
71	Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1166-1172.	4.9	10
72	Uncertainties in real-world decisions on medical technologies. <i>International Journal of Clinical Practice</i> , 2014, 68, 936-940.	1.7	9

#	ARTICLE	IF	CITATIONS
73	Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, 15.	2.4	9
74	Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis. <i>Medical Care</i> , 2018, 56, 365-372.	2.4	9
75	Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1026-1035.	1.9	8
76	Can Genomic Medicine Improve Financial Sustainability of Health Systems?. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 71-77.	3.8	8
77	Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 798-814.	1.9	8
78	Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 333-340.	2.5	8
79	Genomic testing is best integrated into clinical practice when it is actionable. <i>Personalized Medicine</i> , 2020, 17, 5-8.	1.5	8
80	Increases in Suicide Deaths Among Adolescents and Young Adults Following US Food and Drug Administration Antidepressant Boxed Warnings and Declines in Depression Care. <i>Psychiatric Research and Clinical Practice</i> , 2020, 2, 43-52.	2.4	8
81	The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia. <i>Australia and New Zealand Health Policy</i> , 2007, 4, 26.	2.2	7
82	Access to high cost medicines in Australia: ethical perspectives. <i>Australia and New Zealand Health Policy</i> , 2008, 5, 4.	2.2	7
83	Towards integrated care: Australia's new model of care for patients with glaucoma. <i>Medical Journal of Australia</i> , 2010, 193, 200-201.	1.7	7
84	The Importance of High-Quality Evidence of the Long-Term Impact of Nonfatal Events Used in Randomized Controlled Trials: A Case Study of Prasugrel. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 27-29.	4.7	7
85	Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, 7.	2.4	7
86	Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients. <i>Journal of Personalized Medicine</i> , 2017, 7, 17.	2.5	7
87	A Qualitative Study to Develop a Privacy and Nondiscrimination Best Practice Framework for Personalized Wellness Programs. <i>Journal of Personalized Medicine</i> , 2020, 10, 264.	2.5	7
88	Experiences of health care costs among people with employer-sponsored insurance and bipolar disorder. <i>Journal of Affective Disorders</i> , 2021, 281, 41-50.	4.1	7
89	Assessing health outcome data on high-cost medicines in Australia. <i>Medical Journal of Australia</i> , 2006, 184, 411-413.	1.7	6
90	Restricting access to florbetapir: Medicare coverage criteria for diagnostics and drugs are inconsistent: Table 1. <i>BMJ</i> , The, 2015, 351, h3333.	6.0	6

#	ARTICLE	IF	CITATIONS
91	Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. Journal of Personalized Medicine, 2019, 9, 28.	2.5	6
92	Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer. Journal of Personalized Medicine, 2021, 11, 1284.	2.5	6
93	Counter-Point. Medical Care, 2018, 56, 382-383.	2.4	5
94	Counter-Point. Medical Care, 2018, 56, 384-390.	2.4	5
95	Geographic Variations and Time Trends in Cancer Treatments in Taiwan. BMC Public Health, 2018, 18, 89.	2.9	5
96	The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers. Journal of the American Academy of Dermatology, 2019, 81, 867-877.	1.2	5
97	Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders. General Hospital Psychiatry, 2020, 62, 21-27.	2.4	5
98	What motivates the sharing of consumer-generated genomic information?. SAGE Open Medicine, 2020, 8, 205031212091540.	1.8	5
99	Weighing the Association Between BMI Change and Suicide Mortality. Psychiatric Services, 2021, 72, 920-925.	2.0	5
100	Cost burden of hepatitis C virus treatment in commercially insured patients. American Journal of Managed Care, 2019, 25, e379-e387.	1.1	5
101	Sample size is beside the point in policy development research. Australian and New Zealand Journal of Public Health, 2005, 29, 583.	1.8	4
102	National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States. Journal of Alzheimer's Disease, 2016, 54, 1425-1435.	2.6	4
103	The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies. Journal of Personalized Medicine, 2018, 8, 32.	2.5	4
104	When should genomic and exome sequencing be implemented in newborns? A call for an update to newborn screening guidelines. Genetics in Medicine, 2020, 22, 809-810.	2.4	4
105	Integrating Stakeholder Engagement With Claims-Based Research on Health Insurance Design and Bipolar Disorder. Psychiatric Services, 2021, 72, 186-194.	2.0	4
106	Serious Suicide Attempts and Risk of Suicide Death. Crisis, 2021, 42, 343-350.	1.2	4
107	Economic evaluation of whole-genome sequencing in healthy individuals: what can we learn from CEAs of whole-body CT screening?. Genetics in Medicine, 2016, 18, 103-104.	2.4	3
108	Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. JCO Clinical Cancer Informatics, 2019, 3, 1-10.	2.1	3

#	ARTICLE	IF	CITATIONS
109	Genetic variants of <i>PEAR1</i> and ischemic clinical outcomes in coronary artery disease patients: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2021, 22, 641-648.	1.3	3
110	Genetic Testing and/or Counseling for Colorectal Cancer by Health Insurance Type. <i>Journal of Personalized Medicine</i> , 2022, 12, 1146.	2.5	3
111	Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 11-14.	1.9	2
112	Managing comorbidity in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 201-205.	1.9	2
113	Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan. <i>BMJ Open</i> , 2016, 6, e010706.	1.9	2
114	Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer. <i>Value in Health</i> , 2017, 20, 1345-1354.	0.3	2
115	Comment on "Measuring the impact of medicines regulatory interventions" systematic review and methodological considerations" by Goedecke et al. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2167-2168.	2.4	2
116	Diagnosis-based cohort augmentation using laboratory results data: The case of chronic kidney disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 872-877.	1.9	2
117	Exploring African American community perspectives about genomic medicine research: A literature review. <i>SAGE Open Medicine</i> , 2020, 8, 205031212090174.	1.8	2
118	The ethics of grandfather clauses in healthcare resource allocation. <i>Bioethics</i> , 2021, 35, 151-160.	1.4	2
119	Taking on glaucoma care as an interprofessional team. <i>Canadian Journal of Ophthalmology</i> , 2011, 46, 465-467.	0.7	1
120	Authors' reply to Olfson and Schoenbaum, Nardo, Bartlett, Moore, Case, Gotzsche, and Barber and colleagues. <i>BMJ</i> , The, 2014, 349, g5722-g5722.	6.0	1
121	Authors' reply to Mosholder and colleagues. <i>BMJ</i> , The, 2014, 349, g6516-g6516.	6.0	1
122	Response to "Black Box Warning Did Not Cause Increased Suicides". <i>Psychiatric Research and Clinical Practice</i> , 2021, 3, 98-101.	2.4	1
123	Out-of-Pocket Spending Inequity Among High-Deductible Health Plan Members with Bipolar Disorder. <i>Journal of General Internal Medicine</i> , 2021, , 1.	2.6	1
124	Impact of High-Deductible Health Plans on Medication Use Among Individuals With Bipolar Disorder. <i>Psychiatric Services</i> , 2021, 72, 926-934.	2.0	1
125	Payer Decision-Making for Pharmacogenetic Tests: Preliminary Results. <i>Journal of Patient-centered Research and Reviews</i> , 2017, 4, 170-171.	0.9	1
126	The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies. <i>Drug Safety</i> , 2017, 40, 91-100.	3.2	0

#	ARTICLE	IF	CITATIONS
127	Access to High Cost Medicines: An Overview. , 2018, , 1-10.		0
128	Integrating Patient-Reported Outcomes Into Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of Patient-centered Research and Reviews, 2021, 8, 336-339.	0.9	0
129	Insurance Coverage Policies for Guideline-Recommended Genetic Testing for Targeted Cancer Therapies: Preliminary Results. Journal of Patient-centered Research and Reviews, 2016, 3, 193-194.	0.9	0
130	Pharmacoepidemiological Approaches in Health Care. , 2020, , 171-202.		0